Key points are not available for this paper at this time.
Design
Review
May inform future personalized antiplatelet strategies; leaves open prospective validation before clinical adoption.
Interindividual variability in response to antiplatelet therapy results in higher platelet reactivity as well as higher rates of cardiovascular events. Despite substantial effort, the genetic and nongenetic determinants of antiplatelet variability remain poorly understood. Emerging pharmacometabolomic paradigms that integrate systems approaches such as pharmacogenomics have the potential to unveil novel biology regarding disease pathogenesis, reveal the effect of drugs on pathways, and allow better understanding of response variability. Such approaches offer great potential for personalized antiplatelet treatment. Clinical Pharmacology & Therapeutics (2013); 94 5, 570–573. doi:10.1038/clpt.2013.153
No takes yet. Share an insight, caveat, or question.
Lewis et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: